Reducing Benign Breast Biopsies in Women Aged 35 Years or Younger Using a Clinician–AI–Age Triage Strategy
Diagnostics · 25.10.2026 · 16 (21) · 3491
DOI: 10.3390/diagnostics16213491 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 25.10.2026. Verfasst von Nisha Sharma und 2 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Koios Medical (United States).
Abstract (Originalsprache)
Background/Objectives: Symptomatic breast services face increasing diagnostic demand, while younger women with benign-appearing ultrasound lesions frequently undergo biopsy despite a low prevalence of malignancy. This study evaluated whether a rule-based clinical decision algorithm combining patient age, clinician ultrasound assessment and artificial intelligence (AI) decision support could identify a subgroup in whom biopsy might be avoided without excluding malignancy from the biopsy pathway.
Methods
A retrospective analysis was performed using prospectively collected service-evaluation data from 240 patients (254 lesions) attending a large NHS breast unit between May and December 2025. Clinician ultrasound assessment, KOIOS DS Breast AI output and histopathology were recorded. Lesions in women aged ≤ 35 years were eligible for biopsy avoidance when clinician assessment was U2 or U3 and the KOIOS AI assessment was BI-RADS 2. Histopathology was the reference standard. Secondary analyses compared clinician and AI diagnostic performance. An illustrative five-year budget impact analysis was undertaken from the NHS provider perspective.
Results
Among 151 lesions in women aged ≤ 35 years, 146 were benign and five were malignant. The algorithm would have classified 87 lesions for biopsy avoidance (57.6%; 95% CI, 49.3–65.6%). Of these, 67 (77.0%) had a clinician U3 classification. All 87 were benign on histopathology (100%; 95% CI, 95.8–100%), while all five malignant lesions remained in the biopsy pathway. Clinician assessment showed higher specificity than AI (99.1% vs. 75.7%), whereas AI showed higher sensitivity (96.9% vs. 81.3%). Avoidance of 87 biopsies was associated with approximately £85,000 in gross cost offsets during the evaluation period in the illustrative economic model.
Conclusions
The AI-supported clinical decision algorithm could substantially reduce benign biopsy activity in younger women while maintaining cancer detection in this cohort. The small number of malignancies, single-centre design and biopsy population mean that prospective multicentre validation is required before routine clinical implementation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK.
- HecoAnalytics Ltd., Uxbridge UB8 3PQ, UK.
ORCID-Profile: Jack Baldwin
Förderung
- Koios Medical (United States)
Zitieren
APA
Sharma, N., Baldwin, J., & Hendry, S. (2026). Reducing Benign Breast Biopsies in Women Aged 35 Years or Younger Using a Clinician–AI–Age Triage Strategy. Diagnostics, 16(21), 3491. https://doi.org/10.3390/diagnostics16213491
Vancouver
Sharma N, Baldwin J, Hendry S. Reducing Benign Breast Biopsies in Women Aged 35 Years or Younger Using a Clinician–AI–Age Triage Strategy. Diagnostics. 2026;16(21):3491. doi:10.3390/diagnostics16213491
BibTeX
@article{Sharma2026,
author = {Sharma, Nisha and Baldwin, Jack and Hendry, Stuart},
title = {Reducing Benign Breast Biopsies in Women Aged 35 Years or Younger Using a Clinician–AI–Age Triage Strategy},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {21},
pages = {3491},
doi = {10.3390/diagnostics16213491}
}
EUVIMED